Alto Neuroscience (ANRO) Short term Debt (2024 - 2026)
Alto Neuroscience (ANRO) recorded Short term Debt of $3.77 million in Q2 2026, up 76.4% from the prior quarter.
Powered by 
Analysis
Alto Neuroscience (ANRO) Short term Debt (2024 - 2026) Analysis & Trends
At the end of FY2025, Alto Neuroscience reported Short term Debt of $585,000.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn |
| 10 | Alto Neuroscience | 932.10 Mn | 932.10 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.77 Mn |
| Mar 31, 2026 | 2.14 Mn |
| Dec 31, 2025 | 585,000.00 |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 2.32 Mn |
| Mar 31, 2024 | 1.15 Mn |
API Access
Alto Neuroscience Short term Debt API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=short-term-debt&ticker=ANRO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "short-term-debt", "ticker": "ANRO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=short-term-debt&ticker=ANRO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();